MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04002nam a22006137a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
200131s20192019 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1479-5876 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1186/s12967-019-02182-1 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1186/s12967-019-02182-1 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC6933901 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
31878938 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. |
| 251 ## - Source |
|---|
| Source |
Journal of Translational Medicine. 17(1):429, 2019 12 26. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
J. transl. med.. 17(1):429, 2019 12 26. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
J. transl. med.. 17(1):429, 2019 Dec 26. |
| 253 ## - Journal Name |
|---|
| Journal name |
Journal of translational medicine |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2019 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2020 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2020-01-31 |
| 268 ## - Previous citation |
|---|
| -- |
Journal of Translational Medicine. 17(1):429, 2019 Dec 26. |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online through MWHC library: 2003 - present |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
BACKGROUND: Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognostic factor is controversial. This study investigates whether tumoral expression of PD-L1 is a prognostic marker in patients with recurrent and/or metastatic (R/M) HNSCC treated with standard chemotherapy. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: PD-L1 expression, assessed using the VENTANA PD-L1 (SP263) Assay, was not prognostic of OS in patients with R/M HNSCC treated with standard of care chemotherapies. Trial registration ClinicalTrials.gov, NCT02543476. Registered September 4, 2015. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: This retrospective, multicenter, noninterventional study assessed PD-L1 expression on archival R/M HNSCC tissue samples using the VENTANA PD-L1 (SP263) Assay. PD-L1 high was defined as PD-L1 staining of >= 25% TC, with exploratory scoring at TC >= 10% and TC >= 50%. The primary objective of this study was to estimate the prognostic value of PD-L1 status in terms of overall survival (OS) in patients with R/M HNSCC. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: 412 patients (median age, 62.0 years; 79.9% male; 88.2% Caucasian) were included from 19 sites in seven countries. 132 patients (32.0%) had TC >= 25% PD-L1 expression; 199 patients (48.3%) and 85 patients (20.6%) had TC >= 10% and >= 50%, respectively. OS did not differ significantly across PD-L1 expression (at TC >= 25% cutoff median OS: 8.2 months vs TC < 25%, 10.1 months, P = 0.55) or the >= 10% and >= 50% cutoffs (at TC >= 10%, median OS: 9.6 months vs TC < 10%, 9.4 months, P = 0.32, and at TC >= 50%, median OS 7.9 vs TC < 50%, 10.0 months, P = 0.39, respectively). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*B7-H1 Antigen/me [Metabolism] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Biomarkers, Tumor/me [Metabolism] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Neoplasm Recurrence, Local/me [Metabolism] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Squamous Cell Carcinoma of Head and Neck/me [Metabolism] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Squamous Cell Carcinoma of Head and Neck/pa [Pathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Adult |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged, 80 and over |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Disease-Free Survival |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Multivariate Analysis |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Neoplasm Metastasis |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Prognosis |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Retrospective Studies |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Risk Factors |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Health Research Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Shara, Nawar M |
| 790 ## - Authors |
|---|
| All authors |
Baste N, Clayburgh D, Cohen EEW, Fountzilas G, Fujii T, Khaliq A, Kim ES, Lin D, Lipworth L, Mehlhorn H, Melillo G, Pai SI, Resteghini C, Shara N, Shire N, Stokes M, Twumasi-Ankrah P, Wang H, Wildsmith S, Zhang J |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1186/s12967-019-02182-1">https://dx.doi.org/10.1186/s12967-019-02182-1</a> |
| Public note |
https://dx.doi.org/10.1186/s12967-019-02182-1 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
